Value
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 6.7 |
| P/S | 9.5 |
| EV/EBITDA | 6.4 |
| Fwd P/E | 9.4 |
| PEG | 10.0 |
| Analyst target | 3.0 |
- ▸Forward P/E: 9.0x
- ▸PEG: 0.11
- ▸Attractively valued
KMT · Why this verdict
Why Kennametal (KMT) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score5.9/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Three consecutive earnings beats, industry-leading growth near 22% per year, a near-perfect balance-sheet health score, and attractive forward valuation present strong fundamental credentials, but the stock trading above its analyst price target with estimates declining over the past month makes the near-term entry unattractive until the risk/reward resets.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
A near-perfect financial health score across balance-sheet and profitability dimensions signals broad operational and financial strength — a quality foundation that can sustain the growth investment case through industry cycles. Quality breakdown | Financial health score remains near the top decile among industry peers for each of the next four quarters. | →Stable |
| CounterFree cash flow covering only roughly 55% of net income is a meaningful earnings-quality gap; if this shortfall persists, the high health score may mask an underlying cash generation problem that could eventually surface in dividend pressure or incremental debt issuance. | ||
Following the single miss at the oldest quarter in the lookback, the company has delivered three consecutive earnings beats averaging well above 20% above estimates, suggesting a disciplined guidance approach and genuine operational improvement over recent periods. Earnings | Earnings beats continue in at least three of the next four reported quarters, extending the streak. | →Stable |
| CounterForward estimates have declined roughly 8% in the past month, suggesting analysts are resetting expectations lower ahead of potential softness; if the guidance discipline was partly the product of conservative near-term messaging that is now unwinding, the beat streak may be harder to maintain. | ||
Strong earnings growth of approximately 22% per year alongside a forward earnings multiple near 9x positions the company as an industry growth leader at a price well below a full growth premium, offering a potentially favorable growth-at-a-reasonable-price setup. Growth breakdown | Forward earnings multiple expands to at least 12x over the next 12 months as the market recognizes the divergence between growth rate and current valuation. | →Stable |
| CounterAnalyst estimates have declined in the recent period; if consensus continues to revise lower, the seemingly attractive growth multiple may rest on an overstated earnings denominator, and the valuation would look less compelling once estimates fully reset. | ||
With the stock trading above its analyst price target and consensus estimates declining approximately 8% over the past month, the current entry offers more measured downside than upside — the setup does not favor initiating or adding to a position at these levels. Catalyst breakdown | Consensus estimates stabilize or turn positive on a 30-day trailing basis, and the stock re-prices below the analyst target to offer a positive entry cushion. | →Stable |
| CounterEstimate declines may reflect sector-wide caution rather than company-specific deterioration; if the next earnings report again exceeds expectations by a wide margin, analysts could revise sharply higher and the stock could quickly price back above any near-term target reset. | ||
A near-perfect financial health score across balance-sheet and profitability dimensions signals broad operational and financial strength — a quality foundation that can sustain the growth investment case through industry cycles.
→StableQuality breakdown
- Expectation
- Financial health score remains near the top decile among industry peers for each of the next four quarters.
CounterFree cash flow covering only roughly 55% of net income is a meaningful earnings-quality gap; if this shortfall persists, the high health score may mask an underlying cash generation problem that could eventually surface in dividend pressure or incremental debt issuance.
Following the single miss at the oldest quarter in the lookback, the company has delivered three consecutive earnings beats averaging well above 20% above estimates, suggesting a disciplined guidance approach and genuine operational improvement over recent periods.
→StableEarnings
- Expectation
- Earnings beats continue in at least three of the next four reported quarters, extending the streak.
CounterForward estimates have declined roughly 8% in the past month, suggesting analysts are resetting expectations lower ahead of potential softness; if the guidance discipline was partly the product of conservative near-term messaging that is now unwinding, the beat streak may be harder to maintain.
Strong earnings growth of approximately 22% per year alongside a forward earnings multiple near 9x positions the company as an industry growth leader at a price well below a full growth premium, offering a potentially favorable growth-at-a-reasonable-price setup.
→StableGrowth breakdown
- Expectation
- Forward earnings multiple expands to at least 12x over the next 12 months as the market recognizes the divergence between growth rate and current valuation.
CounterAnalyst estimates have declined in the recent period; if consensus continues to revise lower, the seemingly attractive growth multiple may rest on an overstated earnings denominator, and the valuation would look less compelling once estimates fully reset.
With the stock trading above its analyst price target and consensus estimates declining approximately 8% over the past month, the current entry offers more measured downside than upside — the setup does not favor initiating or adding to a position at these levels.
→StableCatalyst breakdown
- Expectation
- Consensus estimates stabilize or turn positive on a 30-day trailing basis, and the stock re-prices below the analyst target to offer a positive entry cushion.
CounterEstimate declines may reflect sector-wide caution rather than company-specific deterioration; if the next earnings report again exceeds expectations by a wide margin, analysts could revise sharply higher and the stock could quickly price back above any near-term target reset.
Per-dimension breakdown
Quality
5.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 3.6 |
| ROA | 3.4 |
| Gross margin | 2.4 |
| Op margin | 5.4 |
| Net margin | 3.2 |
| Current ratio | 8.2 |
| FCF quality | 4.3 |
| Moat | 5.6 |
| Piotroski F | 10.0 |
- ▸Earnings quality warning: 55% FCF/NI
- ▸Strong Piotroski F-Score: 9/9
Growth
8.9/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 7.9 |
| EPS growth | 10.0 |
- ▸Strong growth: 22% YoY
Momentum
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 5.4 |
| erm sentiment | 1.8 |
- ▸Estimates falling as sentiment proxy (-7.9%)
Insider
3.8/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Modest insider selling — $1,583,362 (0.060% of mkt cap)
Peer rank
6.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 7.5 |
| quality rank | 3.8 |
| growth rank | 8.8 |
- ▸Attractive P/E vs peers
- ▸Industry growth leader
Technical
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.6 |
| support resistance | 2.1 |
| 52w position | 6.7 |
| gap | 5.0 |
Risk (lower is worse)
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 5.2 |
| days to cover | 8.0 |
| volatility | 3.4 |
| put call | 10.0 |
| implied vol | 3.0 |
| max pain risk | 3.0 |
| beta | 5.5 |
| debt equity | 8.1 |
- ▸High IV: 62%
- ▸Above max pain $15
Catalyst
5.6/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 1.5 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| dividend safety | 4.8 |
- ▸Estimates down -7.9% (30d)
- ▸Strong earnings: 3B/1M
- ▸Yield trap warning: high yield but unsafe
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more.
Engine technical detail
verdict_path:
L4:PATH_F_HOLDPassed (7)
- MOMENTUM:5.0>=4.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:40d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.9=NEGATIVE
Warning (1)
- MOMENTUM:5.0<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
-0.86
Upside
-10.9%
Downside
12.6%
Sizing output
AVOID
SetupBREAKOUT — Golden cross, above all MAs, RSI 68, MACD bullish
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — Beta 1.37>1.3, MCap $2.6B<$5B
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:5.0>=4.5. Top dim: Growth at 8.9; weakest: Insider at 3.8. No conviction either direction.
The strongest dimensions are Growth at 8.9, Value at 7.5, and Peer rank at 6.2; the weakest are Insider at 3.8, Technical at 3.9, and Sentiment at 4.3. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -0.86 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Following the single miss at the oldest quarter in the lookback, the company has delivered three consecutive earnings beats averaging well above 20% above estimates, suggesting a disciplined guidance approach and genuine operational improvement over recent periods.
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P2Strong earnings growth of approximately 22% per year alongside a forward earnings multiple near 9x positions the company as an industry growth leader at a price well below a full growth premium, offering a potentially favorable growth-at-a-reasonable-price setup.
Trip ifForward EPS estimates decline more than 15% from current levels over 2 consecutive reporting cycles.
- P3A near-perfect financial health score across balance-sheet and profitability dimensions signals broad operational and financial strength — a quality foundation that can sustain the growth investment case through industry cycles.
Trip ifFree cash flow as a percentage of net income falls below 30% for 2 consecutive quarters.
- P4With the stock trading above its analyst price target and consensus estimates declining approximately 8% over the past month, the current entry offers more measured downside than upside — the setup does not favor initiating or adding to a position at these levels.
Trip if30-day consensus estimate change turns positive and sustains above 0% for 2 consecutive months.